Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence.
R HaarsmaA A van LoevezijnM L DonswijkA N ScholtenM T F D Vrancken PeetersFrederieke H van DuijnhovenPublished in: Breast cancer research and treatment (2022)
The incidence of a tumor-positive rSLNB in patients with a negative FDG-PET/CT is low and does not change survival. Therefore, in cN0 patients with IBTR who underwent optimal clinical staging with FDG-PET/CT, we support a patient- and tumor-tailored treatment strategy in which rSLNB may be omitted.